CBLB and neoplasm: Additionally, the combination of therapies targeting CTLA-4 (but not PD-L1) with Cbl-b deficient T cells acts synergistically to enhance anti-tumor response and survival in melanoma mouse models when compared to each of these therapies individually [36], further suggesting that Cbls may be useful clinical targets.